Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Day

Showing results (1041-1050 of 1,098) with videos related to

Pageof 110
Sort By:
Genome Medicine|January 31, 2019
Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathyRoddy Walsh, Francesco Mazzarotto, Nicola Whiffin, et al.
Circulation|May 25, 2023
Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe RegistrySarah Abou Alaiwi, Thomas M Roston, Peter Marstrand, et al.
Circulation. Genomic and Precision Medicine|January 24, 2025
Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic CardiomyopathyAlexandra Butters, Clare Arnott, Joanna Sweeting, et al.
Circulation|January 28, 2020
Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic CardiomyopathyChristopher N Toepfer, Amanda C Garfinkel, Gabriela Venturini, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2008
10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutantsCatherine M Wiscount, Peter D Williams, Lekhanh O Tran, et al.
Circulation|October 2, 2024
Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE RegistryNiccolò Maurizi, Panagiotis Antiochos, Anjali Owens, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
The American Journal of Clinical Nutrition|December 19, 2019
A prospective cohort analysis of gut microbial co-metabolism in Alaska Native and rural African people at high and low risk of colorectal cancerSoeren Ocvirk, Annette S Wilson, Joram M Posma, et al.
Acta Crystallographica. Section B, Structural Science|September 28, 2005
A third blind test of crystal structure predictionG M Day, W D S Motherwell, H L Ammon, et al.
Journal of the American College of Cardiology|July 8, 2026
Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe RegistryConstantin-Cristian Topriceanu, Iswaree Devi Balakrishnan, Christoffer Rasmus Vissing, et al.
Pageof 110

Showing results (1041-1050 of 1,098) with videos related to

Sort By:
Pageof 110
Genome Medicine|January 31, 2019
Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathyRoddy Walsh, Francesco Mazzarotto, Nicola Whiffin, et al.
Circulation|May 25, 2023
Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe RegistrySarah Abou Alaiwi, Thomas M Roston, Peter Marstrand, et al.
Circulation. Genomic and Precision Medicine|January 24, 2025
Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic CardiomyopathyAlexandra Butters, Clare Arnott, Joanna Sweeting, et al.
Circulation|January 28, 2020
Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic CardiomyopathyChristopher N Toepfer, Amanda C Garfinkel, Gabriela Venturini, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2008
10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutantsCatherine M Wiscount, Peter D Williams, Lekhanh O Tran, et al.
Circulation|October 2, 2024
Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE RegistryNiccolò Maurizi, Panagiotis Antiochos, Anjali Owens, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
The American Journal of Clinical Nutrition|December 19, 2019
A prospective cohort analysis of gut microbial co-metabolism in Alaska Native and rural African people at high and low risk of colorectal cancerSoeren Ocvirk, Annette S Wilson, Joram M Posma, et al.
Acta Crystallographica. Section B, Structural Science|September 28, 2005
A third blind test of crystal structure predictionG M Day, W D S Motherwell, H L Ammon, et al.
Journal of the American College of Cardiology|July 8, 2026
Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe RegistryConstantin-Cristian Topriceanu, Iswaree Devi Balakrishnan, Christoffer Rasmus Vissing, et al.
Pageof 110